Related Experiment Videos
Renal cell carcinoma
1University of North Carolina at Chapel Hill, Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599-7305, USA. pgodley@med.unc.edu
Abstract:
Renal cell carcinoma continues to be a difficult malignancy to treat because of its ability to spread asymptomatically and its inherent resistance to conventional chemotherapy. However, molecular genetic studies bring new insights into the pathogenesis of this disorder and may provide new targets against which novel chemotherapeutic agents could be developed. Nephron-sparing surgery is also gaining wider acceptance as favorable long-term, cancer-free survival data emerge from clinical trials. For metastatic disease, cytokine therapy continues to be the mainstay of treatment despite marginal efficacy and a significant side-effect profile.
Insights
Renal cell carcinoma is challenging due to resistance and spread. New molecular insights and nephron-sparing surgery offer improved treatment strategies for this kidney cancer.
Area of Science:
- Oncology
- Molecular Genetics
- Surgical Oncology
Background:
- Renal cell carcinoma (RCC) presents treatment challenges due to asymptomatic metastasis and chemotherapy resistance.
- Conventional treatments for RCC have limited efficacy and significant side effects.
- Emerging research focuses on understanding RCC pathogenesis for targeted therapies.
Purpose of the Study:
- To explore novel therapeutic targets for renal cell carcinoma based on molecular genetic insights.
- To review the current landscape of RCC treatment, including surgical and systemic approaches.
- To highlight the growing acceptance and evidence supporting nephron-sparing surgery for kidney cancer.
Main Methods:
- Review of molecular genetic studies on RCC pathogenesis.
- Analysis of clinical trial data for nephron-sparing surgery outcomes.
- Evaluation of current treatment modalities, including cytokine therapy for metastatic RCC.
Main Results:
- Molecular genetic research is uncovering new pathways and potential therapeutic targets for RCC.
- Nephron-sparing surgery demonstrates favorable long-term, cancer-free survival rates.
- Cytokine therapy remains a primary treatment for metastatic RCC, but with limitations in efficacy and tolerability.
Conclusions:
- Advances in understanding RCC molecular genetics are paving the way for novel chemotherapeutic agents.
- Nephron-sparing surgery is an increasingly viable and effective option for kidney cancer treatment.
- Further research is needed to improve systemic therapies for metastatic renal cell carcinoma.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Urinary Tract Calculi I: Introduction
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Nephrons